Search Results

The intended use of the Sysmex® CA-500 is as a fully automated, computerized blood plasma coagulation analyzer for in vitro diagnostic use in clinical laboratories.

The instrument uses citrated human plasma to perform the following parameters and calculated parameters:

Clotting Analysis Parameters

• Prothrombin Time (PT) ●
• Activated Partial Thromboplastin Time (APTT) .
• Fibrinogen (Clauss) .

Chromogenic Analysis Parameters

• Antithrombin III ●
• Protein C t

Calculated Parameters

• PT Ratio .
• PT INR ●
• Batroxobin .
• Protein C ●
• Heparin .
• Derived Fibrinogen .

The Sysmex® CA-500 is intended for use as an automated citrated human plasma coagulation analyzer.

{
  "acceptance_criteria_and_study": {
    "1._table_of_acceptance_criteria_and_reported_device_performance": {
      "Method Comparison Studies": {
        "Predicate Device": "Behring Coagulation Timer (BCT) or Behring Fibrintimer A (BFA)",
        "Acceptance Criteria (Implicit)": "Coefficient of Correlation (r) > 0.95 for method comparison to predicate device",
        "Reported Device Performance": {
          "Batroxobin (vs. BCT)": "r = 0.984",
          "Protein C, Chromogenic (vs. BCT)": "r = 0.963",
          "Heparin, Chromogenic (vs. BCT)": "r = 0.977",
          "Protein C, Coagulometric (vs. BFA)": "r = 0.974"
        }
      },
      "Precision Studies": {
        "Acceptance Criteria (Implicit)": "Low %CV (Coefficient of Variation) for within-run, between-run, and total precision.",
        "Reported Device Performance": {
          "Batroxobin Time (CPN)": "Within-Run %CV = 1.0, Between-Run %CV = 1.2, Total %CV = 1.5",
          "Batroxobin Time (Pool Plasma 2)": "Within-Run %CV = 1.9, Between-Run %CV = 0.7, Total %CV = 1.9",
          "Protein C Coagulometric (CPN)": "Within-Run %CV = 4.8, Between-Run %CV = 3.6, Total %CV = 5.8",
          "Protein C Coagulometric (CPP)": "Within-Run %CV = 9.0, Between-Run %CV = 6.2, Total %CV = 10.4",
          "Protein C Chromogenic (CPN)": "Within-Run %CV = 1.6, Between-Run %CV = 1.0, Total %CV = 1.8",
          "Protein C Chromogenic (CPP)": "Within-Run %CV = 3.6, Between-Run %CV = 1.4, Total %CV = 3.6",
          "Heparin (Ci-Trol Hep Hi)": "Within-Run %CV = 4.0, Between-Run %CV = 5.2, Total %CV = 6.4",
          "Heparin (Ci-Trol Hep Lo)": "Within-Run %CV = 5.6, Between-Run %CV = 4.7, Total %CV = 7.1"
        }
      }
    },
    "2._sample_size_used_for_the_test_set_and_the_data_provenance": {
      "Method Comparison Studies": {
        "Batroxobin": "183 samples",
        "Protein C, Chromogenic": "114 samples",
        "Heparin, Chromogenic": "53 samples",
        "Protein C, Coagulometric": "Not explicitly stated for BFA comparison, but implied to be similar numbers for other tests (e.g., 114 range for Protein C tests with BCT)",
        "Data Provenance": "Specimens were evaluated from apparently healthy individuals and from patients with different pathological conditions which are expected to affect the results for a particular assay. Country of origin not specified, but likely within Dade Behring's operational regions (e.g., USA, Europe). Retrospective or prospective not specified, but typically prospective for method comparison studies."
      },
      "Precision Studies": {
        "Batroxobin Time (CPN/Pool Plasma 2)": "40 samples per level",
        "Protein C Coagulometric (CPN/CPP)": "40 samples per level",
        "Protein C Chromogenic (CPN/CPP)": "40 samples per level",
        "Heparin (Ci-Trol Hep Hi/Lo)": "32 samples per level",
        "Data Provenance": "Control materials (CPN, CPP, Ci-Trol Hep Hi/Lo) and pooled plasma. Country of origin not specified. Prospective testing."
      }
    },
    "3._number_of_experts_used_to_establish_the_ground_truth_for_the_test_set_and_the_qualifications_of_those_experts": "Not applicable. This device is an automated coagulation analyzer, and its performance is evaluated against established laboratory methods (predicate devices) and internal quality control samples, not against expert human interpretation of clinical data or images.",
    "4._adjudication_method_for_the_test_set": "Not applicable. Ground truth for performance studies of automated laboratory analyzers is typically established by the results from a legally marketed predicate device or by standard reference materials, not through expert adjudication.",
    "5._if_a_multi_reader_multi_case_(MRMC)_comparative_effectiveness_study_was_done,_If_so,_what_was_the_effect_size_of_how_much_human_readers_improve_with_AI_vs_without_AI_assistance": "Not applicable. This is an automated laboratory analyzer, not an AI-assisted diagnostic imaging or interpretation device that would involve human readers.",
    "6._if_a_standalone_(i.e._algorithm_only_without_human-in-the-loop_performance)_was_done": "Yes. The studies presented (method comparison and precision) evaluate the standalone performance of the Sysmex® Automated Coagulation Analyzer CA-500 against predicate devices and internal controls. There is no human-in-the-loop component for the analytical performance itself.",
    "7._the_type_of_ground_truth_used": "The ground truth for the test set (method comparison) was established by the measurements obtained from legally marketed predicate devices (Behring Coagulation Timer (BCT) and Behring Fibrintimer A (BFA)). For precision studies, it was based on the expected values of control materials and pooled plasmas.",
    "8._the_sample_size_for_the_training_set": "Not applicable. This is an automated laboratory analyzer, not a machine learning or AI-based device that typically requires a 'training set'. Its operational parameters are likely calibrated during manufacturing and validated through performance testing.",
    "9._how_the_ground_truth_for_the_training_set_was_established": "Not applicable for the same reasons as above. The device's internal algorithms are based on established coagulation measurement principles, not learned from a training dataset."
  }
}

Ask a specific question about this device

The intended use of the Sysmex® CA-500 is as a fully automated, computerized blood plasma coagulation analyzer for in vitro diagnostic use in clinical laboratories.

The instrument uses citrated human plasma to perform the following parameters and calculated parameters:

Clotting Analysis Parameters

• Prothrombin Time (PT) ●

• Activated Partial Thromboplastin Time (APTT) .

• Fibrinogen (Clauss) .

• Batroxobin .

• Protein C .
  Heparin

.

• · Thrombin Time
• Extrinsic Factors (II, V, VII, X) .
• Intrinsic Factors (VIII, IX, XI, XII) .

Chromogenic Analysis Parameters

• Antithrombin III .
• . Protein C

Calculated Parameters

• PT Ratio ●
• . PT INR
• . Derived Fibrinogen
• Factor Assays % Activity .

The Sysmex® CA-500 is intended for use as an automated blood plasma coagulation analyzer.

The Sysmex® Automated Coagulation Analyzer CA-500 is intended for use as an automated blood plasma coagulation analyzer. The device's performance was compared to a predicate device, the Behring Coagulation Timer (BCT).

1. Table of Acceptance Criteria and Reported Device Performance:

The document describes "in-house correlation studies" to demonstrate that the performance claims of the proposed device are similar to the predicate device. The acceptance criteria can be inferred from the reported performance, which shows high correlation coefficients (r ≥ 0.960) between the CA-500 and the BCT for the measured coagulation factors.

Note: The specific numerical acceptance criteria (e.g., r > 0.95) are not explicitly stated in the provided text but are inferred from the reported strong correlations.

2. Sample Size Used for the Test Set and Data Provenance:

• Sample Size (Test Set):
  • Coagulation Factor VII: 80 specimens
  • Coagulation Factor VIII: 94 specimens
• Data Provenance: The specimens were evaluated from "apparently healthy individuals and from patients with different pathological conditions which are expected to affect the results for a particular assay." The country of origin is not specified but the manufacturing site is Kobe, Japan, and the distributor is Dade Behring Inc. in Newark, DE, USA. The studies are described as "in-house correlation studies," suggesting they were conducted by the manufacturer or a contracted entity. The data is prospective, as samples were "evaluated" during these studies.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

The document does not mention the use of experts to establish ground truth in the context of the correlation studies. The ground truth for the device's performance is established by comparison to a predicate device, the Behring Coagulation Timer (BCT), rather than an independent expert consensus on patient conditions.

4. Adjudication Method for the Test Set:

Not applicable. The study is a method comparison study between the proposed device and a predicate device, not an assessment requiring expert adjudication of results.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:

No, an MRMC comparative effectiveness study was not done. The study focuses on the analytical performance of the device compared to a predicate device, not on human reader performance with or without AI assistance.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:

Yes, the study describes the standalone performance of the Sysmex® Automated Coagulation Analyzer CA-500 in comparison to the predicate device. It evaluates the device's ability to measure coagulation factors.

7. The Type of Ground Truth Used:

The "ground truth" for this study is the measurements obtained from the predicate device, the Behring Coagulation Timer (BCT). The study assesses the correlation and agreement of the Sysmex CA-500 with a previously cleared device, not against absolute pathological or outcomes data independent of a measurement instrument.

8. The Sample Size for the Training Set:

The document does not mention a "training set" as this is not an AI/machine learning device that would typically undergo a training phase. It is an automated coagulation analyzer being evaluated for substantial equivalence to a predicate device based on its analytical performance.

9. How the Ground Truth for the Training Set was Established:

Not applicable, as there is no mention of a training set for this device in the provided text.

Ask a specific question about this device